Cost-effectiveness analysis of cervical cancer screening strategies in urban China
10.3760/cma.j.issn.0253-3766.2019.02.015
- VernacularTitle: 中国城镇地区子宫颈癌筛查的卫生经济学评价
- Author:
Jieru PENG
1
;
Siyuan TAO
1
;
Ying WEN
2
;
Xue YANG
1
;
Jianqiao MA
1
;
Fei ZHAO
1
;
Zhiyu CHEN
1
;
Guiting ZHANG
1
;
Youlin QIAO
3
;
Fanghui ZHAO
3
;
Chunxia YANG
1
Author Information
1. Department of Epidemiology and Biostatistics, West China School of Public Health, Sichuan University, Chengdu 610041, China
2. Key Laboratory of Molecular Biology of Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China
3. Department of Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Cervical neoplasms;
Screening;
Markov model;
Health economic analysis
- From:
Chinese Journal of Oncology
2019;41(2):154-160
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the most economically feasible cervical cancer screening strategies in urban China.
Methods:A series of Markov models were constructed to evaluate health and economic outcomes of different screening strategies. There were 24 screening strategies including four screening methods: liquid-based cytology (LBC), human papillomavirus (HPV) DNA genotyping, HPV DNA genotyping with LBC triage (HPV DNA+ LBC), HPV DNA genotyping and LBC co-testing (HPV DNA-LBC), along with three intervals (every 1, 3 or 5 years) and two starting age for screening (30 or 35 years old) were compared. Models parameters were obtained from a cervical cancer screening study in urban China and literature reviews.
Results:The cumulative incidence and mortality risk of cervical cancer declined over 69% and 82% respectively for each screening strategy as compared with the no screening scenario. LBC every five years starting from 35 years old strategy cost the least (RMB 690 per capita) and could save life years compared with no screening. The cost effectiveness ratios of 24 strategies ranged from -10 903 to 117 992 RMB per life year saved. All strategies were cost-effective compared to no screening. In the incremental cost-effectiveness analysis, LBC every 5 years starting from 30 strategy, HPV DNA genotyping every 3 years starting from 30 strategy, LBC every 3 years starting from 30 strategy and LBC every year starting from 30 strategy were dominant strategies.
Conclusions:Screening can effectively prevent cervical cancer. In urban Chinese areas with insufficient socioeconomic resources, LBC every 5 years from 35 years old strategy is recommended. In relatively more affluent areas, LBC every 5 years from 30 years old strategy, LBC every 3 years from 30 years old strategy, HPV DNA genotyping every 3 years from 30 years old strategy, and LBC every year from 30 years old strategy are recommended successively.
